We are live on ! Find out more
AUPH icon

Aurinia Pharmaceuticals
AUPH

17 hedge funds and large institutions have $19.7M invested in Aurinia Pharmaceuticals in 2016 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 7 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 2

17% more capital invested

Capital invested by funds: $16.8M → $19.7M (+$2.92M)

6% more funds holding

Funds holding: 16 → 17 (+1)

71% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 7

Holders
17
Holders Change
+1
Holders Change %
+6.25%
% of All Funds
0.45%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
2
Reduced
7
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
A
Abingworth
United Kingdom
+$214K
2
Goldman Sachs
Goldman Sachs
New York
+$51.1K
3
RG
Redmile Group
California
+$7.5K
4
Morgan Stanley
Morgan Stanley
New York
+$2.66K
5
Bank of America
Bank of America
North Carolina
+$2.42K

Top Sellers

Rank Fund Capital Flow
1
EAM
EverPoint Asset Management
Connecticut
-$143K
2
LOAMU
Lombard Odier Asset Management (USA)
New York
-$37.3K
3
UBS Group
UBS Group
Switzerland
-$36K
4
TRCT
Tower Research Capital (TRC)
New York
-$18.1K
5
Renaissance Technologies
Renaissance Technologies
New York
-$16.4K
Name Holding Trade Value Shares
Change 		Change in
Stake
NMC
1
NEA Management Company
Maryland
$7.41M – – –
GPP
2
Great Point Partners
Connecticut
$7.19M – – –
BBA
3
Baker Bros. Advisors
New York
$2.08M – – –
EAM
4
EverPoint Asset Management
Connecticut
$1.75M -$143K -59,210 -9%
Millennium Management
5
Millennium Management
New York
$423K – – –
LOAMU
6
Lombard Odier Asset Management (USA)
New York
$292K -$37.3K -15,431 -13%
A
7
Abingworth
United Kingdom
$256K +$214K +88,307 New
Renaissance Technologies
8
Renaissance Technologies
New York
$88K -$16.4K -6,800 -18%
Goldman Sachs
9
Goldman Sachs
New York
$61K +$51.1K +21,118 New
RG
10
Redmile Group
California
$58K +$7.5K +3,100 +19%
Royal Bank of Canada
11
Royal Bank of Canada
Ontario, Canada
$31K -$48 -20 -0.2%
Bank of Montreal
12
Bank of Montreal
Ontario, Canada
$22K – – –
UBS Group
13
UBS Group
Switzerland
$6K -$36K -14,891 -88%
Morgan Stanley
14
Morgan Stanley
New York
$6K +$2.66K +1,100 +104%
Bank of America
15
Bank of America
North Carolina
$3K +$2.42K +1,000 New
TRCT
16
Tower Research Capital (TRC)
New York
$1K -$18.1K -7,467 -96%
PAIM
17
Punch & Associates Investment Management
Minnesota
– -$741 -300 Closed
Toronto Dominion Bank
18
Toronto Dominion Bank
Ontario, Canada
– -$36 -15 -29%

AUPH Hedge Fund Activity: Q1 2016 in Review

17 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Aurinia Pharmaceuticals (AUPH) for Q1 2016, worth a combined $19.7M — up 17% from $16.8M a quarter earlier.

Buyers outnumbered sellers: 3 funds opened new AUPH positions and 2 closed out — a net gain of 1 holder — while 2 added to existing stakes and 7 trimmed.

The largest buyer was Abingworth, opening a new position worth an estimated $214K. The largest seller was EverPoint Asset Management, cutting an estimated $143K.

  • 17 institutional investors held Aurinia Pharmaceuticals (AUPH) as of Q1 2016, up from 16 in Q4 2015.
  • Funds reported $19.7M of Aurinia Pharmaceuticals stock for Q1 2016, up 17% quarter-over-quarter.
  • 3 funds opened new Aurinia Pharmaceuticals positions in Q1 2016 and 2 closed out, a net change of +1 holder.
  • The largest Aurinia Pharmaceuticals buyer in Q1 2016 was Abingworth, an estimated $214K added.
  • The largest Aurinia Pharmaceuticals seller in Q1 2016 was EverPoint Asset Management, an estimated $143K sold.

Based on aggregated 13F filings for Q1 2016.